Document is current
Any future updates will be listed below
-
Authors
Silva, Joana C. https://orcid.org/0000-0001-6502-7026
Dwivedi, Ankit
Moser, Kara A.
Sissoko, Mahamadou S.
Epstein, Judith E.
Healy, Sara A. https://orcid.org/0000-0003-3078-6094
Lyke, Kirsten E.
Mordmüller, Benjamin https://orcid.org/0000-0001-9101-2768
Kremsner, Peter G. https://orcid.org/0000-0002-3926-4113
Duffy, Patrick E. https://orcid.org/0000-0002-4483-5005
Murshedkar, Tooba
Sim, B. Kim Lee
Richie, Thomas L. https://orcid.org/0000-0002-2946-5456
Hoffman, Stephen L. https://orcid.org/0000-0002-0700-9505
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (U19AI110820 and R01AI141900)
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (5R44AI058375-10 and 5R44AI055229-11)
- License Information
-
More Information
Article History
Received: 10 February 2021
Accepted: 24 May 2022
First Online: 13 June 2022
Competing interests
: T.L.R., T.M., B.K.L.S., and S.L.H. are salaried employees of Sanaria Inc., the developer, and owner of PfSPZ Vaccine and PfSPZ Challenge (7G8). In addition, S.L.H. and B.K.L.S. have a financial interest in Sanaria Inc. No other authors declare competing interests.
